{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:04:52Z","timestamp":1790730292154,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.vhri.2020.11.010","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:10:37Z","timestamp":1618359037000},"page":"216-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cost-Effectiveness of Juluca for Human Immunodeficiency Virus Infection Treatment in Virologically Suppressed Adults in Taiwan"],"prefix":"10.1016","volume":"24","author":[{"given":"Sarah-Jane","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung-Yuan","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang-Tz","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Ying","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2020.11.010_bib2","unstructured":"Joint United Nations Progamme on HIV\/AIDS. 90\u201390\u201390 - An ambitious treatment target to help end the AIDS epidemic."},{"key":"10.1016\/j.vhri.2020.11.010_bib3","series-title":"Taiwan CDC HIV monthly report 2018-08","year":"2018"},{"key":"10.1016\/j.vhri.2020.11.010_bib4","series-title":"HIV physician training workshop","year":"2018"},{"issue":"1","key":"10.1016\/j.vhri.2020.11.010_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13181-013-0325-8","article-title":"A\u00a0review of the toxicity of HIV medications","volume":"10","author":"Margolis","year":"2014","journal-title":"J\u00a0Med Toxicol"},{"issue":"7","key":"10.1016\/j.vhri.2020.11.010_bib6","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/QAD.0b013e328351f68f","article-title":"Association of tenofovir exposure with kidney disease risk in HIV infection","volume":"26","author":"Scherzer","year":"2012","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.vhri.2020.11.010_bib7","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32835192ae","article-title":"Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents","volume":"26","author":"Bedimo","year":"2012","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.vhri.2020.11.010_bib8","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/15284336.2016.1243363","article-title":"Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection","volume":"17","author":"Bedimo","year":"2016","journal-title":"HIV Clin Trials"},{"issue":"2","key":"10.1016\/j.vhri.2020.11.010_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40121-018-0201-6","article-title":"A\u00a0review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population","volume":"7","author":"Chawla","year":"2018","journal-title":"Infect Dis Ther"},{"issue":"8","key":"10.1016\/j.vhri.2020.11.010_bib10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40266-013-0093-9","article-title":"The next therapeutic challenge in HIV: polypharmacy","volume":"30","author":"Edelman","year":"2013","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.vhri.2020.11.010_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/11313810-000000000-00000","article-title":"The cost and incidence of prescribing errors among privately insured HIV patients","volume":"28","author":"Hellinger","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.vhri.2020.11.010_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.cger.2012.01.002","article-title":"Polypharmacy, adverse drug reactions, and geriatric syndromes","volume":"28","author":"Shah","year":"2012","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.vhri.2020.11.010_bib13","unstructured":"Llibre, JM. , Hung C, Brinson C, et\u00a0al. Phase III SWORD 1&2: switch to DTG+RPV maintains virologic suppression through 48 wks. Presented at: Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, WA."},{"key":"10.1016\/j.vhri.2020.11.010_bib14","unstructured":"Orkin C, Khuong-Josses M-A, Lutz T, et\u00a0al. Safety and Efficacy of DTG+RPV in the Phase III SWORD-1 and SWORD-2 Studies: 48 Week Subgroup Analysis by Baseline Third Agent Class and Geographic Location. Presented at: 16th European AIDS Conference; Milan, Italy,\u00a02017."},{"key":"10.1016\/j.vhri.2020.11.010_bib15","series-title":"Estimating Health Outcomes in HIV Infected Patients Treated with a Dual Regimen of Dolutegravir and Rilpivirine in Europe","year":"2018"},{"issue":"2","key":"10.1016\/j.vhri.2020.11.010_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148231","article-title":"Dual therapy treatment strategies for the management of patients infected with HIV: a systematic review of current evidence in ARV-naive or ARV-experienced, virologically suppressed patients","volume":"11","author":"Baril","year":"2016","journal-title":"PloS One"},{"issue":"10","key":"10.1016\/j.vhri.2020.11.010_bib18","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3018(17)30109-1","article-title":"Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV\/AIDS: a systematic review and network meta-analysis","volume":"4","author":"Kanters","year":"2017","journal-title":"Lancet HIV"},{"issue":"4","key":"10.1016\/j.vhri.2020.11.010_bib19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archinte.165.4.416","article-title":"The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy","volume":"165","author":"d\u2019Arminio Monforte","year":"2005","journal-title":"Arch Intern Med"},{"issue":"13","key":"10.1016\/j.vhri.2020.11.010_bib20","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1503\/cmaj.071416","article-title":"Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents","volume":"178","author":"Berger","year":"2008","journal-title":"CMAJ"},{"issue":"3","key":"10.1016\/j.vhri.2020.11.010_bib21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jocd.2010.04.005","article-title":"Normative bone mineral density z-scores for Canadians aged 16 to 24 years: the Canadian Multicenter Osteoporosis Study","volume":"13","author":"Zhou","year":"2010","journal-title":"J\u00a0Clin Densitom"},{"issue":"22","key":"10.1016\/j.vhri.2020.11.010_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003780","article-title":"Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir","volume":"95","author":"Gianotti","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.vhri.2020.11.010_bib23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care","volume":"117","author":"D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.vhri.2020.11.010_bib24","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s001980170006","article-title":"Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds","volume":"12","author":"Kanis","year":"2001","journal-title":"Osteoporos Int"},{"issue":"7","key":"10.1016\/j.vhri.2020.11.010_bib25","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1524-4733.2008.00326.x","article-title":"A\u00a0predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy","volume":"11","author":"Kauf TL Roskell","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2020.11.010_bib26","series-title":"Self-Reported Population Health: An International Perspective based on EQ-5D","year":"2014"},{"issue":"2","key":"10.1016\/j.vhri.2020.11.010_bib27","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1177\/0272989X98018002S11","article-title":"A\u00a0Monte Carlo simulation of advanced HIV disease application to prevention of CMV infection","volume":"18","author":"Paltiel","year":"1998","journal-title":"Med Decis Making"},{"key":"10.1016\/j.vhri.2020.11.010_bib28","author":"Ara"},{"issue":"2","key":"10.1016\/j.vhri.2020.11.010_bib29","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/jbmr.1758","article-title":"An economic evaluation: simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures","volume":"28","author":"Nshimyumukiza","year":"2013","journal-title":"J\u00a0Bone Mineral Res"},{"issue":"6","key":"10.1016\/j.vhri.2020.11.010_bib30","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1111\/j.1523-1755.2005.00752.x","article-title":"Health-related quality of life and estimates of utility in chronic kidney disease","volume":"68","author":"Gorodetskaya","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.vhri.2020.11.010_bib31","series-title":"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents","year":"2009"},{"key":"10.1016\/j.vhri.2020.11.010_bib32","article-title":"Association of adherence to antiretroviral therapy with economic burden of cardiovascular disease in HIV-infected population","author":"Liao","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"11","key":"10.1016\/j.vhri.2020.11.010_bib33","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00296-016-3551-y","article-title":"Medical costs incurred by organ damage caused by active disease, comorbidities and side effect of treatments in systemic lupus erythematosus patients: a Taiwan nationwide population-based study","volume":"36","author":"Chiu","year":"2016","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.vhri.2020.11.010_bib34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11657-017-0385-5","article-title":"Age- and gender-specific epidemiology, treatment patterns, and economic burden of osteoporosis and associated fracture in Taiwan between 2009 and 2013","volume":"12","author":"Wang","year":"2017","journal-title":"Arch Osteoporos"},{"issue":"12","key":"10.1016\/j.vhri.2020.11.010_bib35","doi-asserted-by":"crossref","first-page":"946","DOI":"10.7326\/0003-4819-126-12-199706150-00003","article-title":"Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection","volume":"126","author":"Mellors","year":"1997","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.vhri.2020.11.010_bib36","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40273-013-0098-6","article-title":"A\u00a0methodological review of models used to estimate the cost effectiveness of antiretroviral regimens for the treatment of HIV infection","volume":"31","author":"Mauskopf","year":"2013","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.vhri.2020.11.010_bib37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/01.qai.0000160406.08924.a2","article-title":"Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease","volume":"39","author":"Sax","year":"2005","journal-title":"J\u00a0Acquir Immune Defic Syndr"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109921000157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109921000157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:12:28Z","timestamp":1761941548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109921000157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":35,"alternative-id":["S2212109921000157"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2020.11.010","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Juluca for Human Immunodeficiency Virus Infection Treatment in Virologically Suppressed Adults in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2020.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 ISPOR--The professional society for health economics and outcomes research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}